BioCentury | Aug 14, 2019
Financial News

D&D raises $137M to fund inflammation tech out of JHU

...is inflammation. Octave Life Sciences and Smilegate Investments co-led the round, with participation from InterVest, Magna Investment...
BioCentury | Jul 20, 2018
Financial News

Neuraly raises $36M series A to develop microglia-targeted PD candidate

...led by new investor D&D Pharmatech (Gyeonggi-do, Korea). Korean venture funds Smilegate, InterVest, LB Investment, Magna Investment...
BioCentury | Jul 18, 2018
Financial News

Neuraly debuts with $36M to target neurodegenerative diseases

...led by new investor D&D Pharmatech (Gyeonggi-do, Korea). Korean venture funds Smilegate, InterVest, LB Investment, Magna Investment...
Items per page:
1 - 3 of 3
BioCentury | Aug 14, 2019
Financial News

D&D raises $137M to fund inflammation tech out of JHU

...is inflammation. Octave Life Sciences and Smilegate Investments co-led the round, with participation from InterVest, Magna Investment...
BioCentury | Jul 20, 2018
Financial News

Neuraly raises $36M series A to develop microglia-targeted PD candidate

...led by new investor D&D Pharmatech (Gyeonggi-do, Korea). Korean venture funds Smilegate, InterVest, LB Investment, Magna Investment...
BioCentury | Jul 18, 2018
Financial News

Neuraly debuts with $36M to target neurodegenerative diseases

...led by new investor D&D Pharmatech (Gyeonggi-do, Korea). Korean venture funds Smilegate, InterVest, LB Investment, Magna Investment...
Items per page:
1 - 3 of 3